Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

658
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
658

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report.

Journal of human immunity·2026
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

Plasticity under pressure: biology and detection of lineage switch in acute leukemia.

Leukemia·2026
Same author

Minimal Residual Disease by High-Throughput Sequencing in Standard Risk-Favorable Pediatric B-Lymphoblastic Leukemia.

Blood advances·2026
Same author

Flow cytometric quantitation of CD34+ progenitors in peripheral blood: an adjunct tool for diagnostic evaluation of pancytopenia.

American journal of clinical pathology·2026
Same author

Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.

Leukemia·2026

Related Experiment Video

Updated: Jun 6, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K

CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting

Samy Jambon1, Jianping Sun1, Shawn Barman1

  • 1Division of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.

Blood Cancer Discovery
|December 3, 2024
PubMed
Summary

This study introduces "IF-THEN" SynNotch-gated CAR-T cells for acute myeloid leukemia (AML). This novel approach reduces side effects and improves treatment efficacy by targeting specific cancer cell markers.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.2K

Related Experiment Videos

Last Updated: Jun 6, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.2K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for acute myeloid leukemia (AML).
  • Existing CAR-T therapies face challenges including off-tumor toxicity and cytokine release syndrome.
  • Targeting CD33 and CD123 antigens is a key strategy in AML treatment.

Purpose of the Study:

  • To develop an "IF-THEN" SynNotch-gated CAR-T cell strategy for AML.
  • To reduce off-tumor toxicity and improve the safety profile of CAR-T therapy in AML.
  • To enhance T-cell function and therapeutic outcomes in AML.

Main Methods:

  • Engineered "IF-THEN" SynNotch receptors to gate CAR-T cell activity.
  • Designed CAR-T cells targeting CD33 and CD123 antigens expressed on AML cells.
  • Evaluated T-cell phenotype, expansion, and in vivo efficacy in preclinical AML models.

Main Results:

  • "IF-THEN" SynNotch-gated CAR-T cells demonstrated reduced off-tumor toxicity.
  • Enhanced T-cell phenotype and improved expansion were observed.
  • Preservation of hematopoietic stem and progenitor cells (HSPCs) and mitigation of cytokine release syndrome were achieved.

Conclusions:

  • "IF-THEN" SynNotch-gated CAR-T cell therapy offers a safer and more effective approach for AML.
  • This strategy addresses critical limitations of current CAR-T therapies for AML.
  • Further development holds potential for improved AML treatment outcomes.